Drug
Olezarsen
Olezarsen: highest development phase Phase 3, developed by Ionis Pharmaceuticals. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Ionis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Olezarsen NCT07727538 | Phase 3 | Familial Chylomicronemia Syndrome |
| Olezarsen NCT04568434 | Phase 3 | Familial Chylomicronemia Syndrome |
| Olezarsen NCT05079919 | Phase 3 | Severe Hypertriglyceridemia |
| Olezarsen NCT05610280 | Phase 3 | Hypertriglyceridemia |
| Olezarsen NCT05681351 | Phase 3 | Severe Hypertriglyceridemia |
| Olezarsen NCT05355402 | Phase 2 | Hypertriglyceridemia |
Latest
No recent events.
Follow Olezarsen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.